BCIQ Profiles

Company Profile Report

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least one other biosimilar

Read the full 386 word article

How to gain access

Continue reading with a
two-week free trial.